EN DE
Watch Revvity Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Revvity Inc. (RVTY) fair value: what the stock is really worth

As of Nov 4, 2026: fair value (intrinsic value) of Revvity Inc. stock $37.00, price $159, that is 76.8% below the price, quality 68 out of 100. Rating: strongly overvalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

RI Revvity Inc. logo Some data Nov 4, 2026

Revvity Inc.

RVTY · US
Solid, but very expensive

Our calculation puts a fair price 77% below what the stock costs today.

Quality 68/100
Low debt
Generates free cash flow
0.2% dividend yield · Well covered
Positive coverage
Thin margins · 8.2% net margin (TTM)
Insiders sold $1.3M (6M)
Some data
Costs 76 times its yearly profit.
Fair value $37.00 · Strongly overvalued (−76.8%)
Weak Growth (revenue 5y −5.5 %/yr in USD)
Trails peers (4/14)
Narrow moat 44/100 · thin data

Risks from the AI analysis

🚩AI could cut demand for screening tools🚩China DRG reforms could squeeze diagnostics margins
Watch Revvity Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$198.75 $81.47 Fair Value $37.00 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range $81.47 – $198.75 · fair‑value band $27.61 – $47.21 · the $159.43 price screens above the $37.00 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Revvity in your weekly email

Every Wednesday you see whether Revvity is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Revvity, Inc. provides health sciences solutions, technologies, and services.

Show moreShow less

The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.

Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions.

The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery.

It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names.

The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Stock analysis

Revvity Inc. (RVTY) currently trades at $159.43, while our model-based Fair Value estimate is $37.00, 77% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $42.36 per share, and 0 of the 22 models we run sit above the $159.43 price.

Bear case: the Earnings-Based group reads lowest at $15.17, and 22 of the 22 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $27.61 (bear) to $47.21 (bull), the price of $159.43 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revvity Inc. reported revenue of $2.9B in FY2025 versus $3.8B in FY2021, a compound −7.1%/yr. Reported net income was $242M in FY2025, compounding −28.9%/yr from FY2021.

Key figures

Market cap $17.8B Large · P/E ratio 76.3 · P/S ratio 6.12 · EPS (TTM) $2.09 · Dividend yield 0.2% · Net margin 8.2% · Return on equity 3.2% · Return on assets (EBIT) 4.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 4% below its 52-week high and 94% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −77%, RVTY screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely ($3.62 to $73.25). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear $27.61 Fair Value $37.00 Bull $47.21
Price $159.43 · Downside -76.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($1.54 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $37.34 $57.09 $85.19 80
Growth DCF $38.98 $57.66 $83.05 78
Owner Earnings $34.53 $53.23 $79.83 76
All 22 models by family
DCF Models
FCF DCF $37.34 $57.09 $85.19 80
Owner Earnings $34.53 $53.23 $79.83 76
5Y Revenue Exit $21.50 $35.33 $52.43 72
5Y EBITDA Exit $43.30 $73.25 $107.26 74
5Y P/E Exit $23.96 $39.61 $55.35 70
10Y Revenue Exit $26.46 $39.56 $54.62 67
10Y EBITDA Exit $40.49 $64.41 $92.60 68
10Y P/E Exit $28.74 $42.36 $56.65 64
Earnings-Based
Graham-Dodd $14.73 $29.73 $37.41 66
EPV $10.98 $15.17 $18.79 73
Dividend Discount
Gordon GGM $2.60 $3.70 $4.81 69
DDM Multi-Stage $2.60 $3.62 $4.75 67
Multiples
P/E Multiple $35.74 $47.65 $59.56 63
P/S Multiple $27.61 $36.82 $46.02 58
EV/EBIT $17.48 $31.06 $44.65 63
EV/EBITDA $48.43 $72.33 $96.23 66
EV/Revenue $5.82 $18.28 $30.74 49
Growth DCF
Growth DCF $38.98 $57.66 $83.05 78
Rev-Margin DCF $21.50 $36.28 $52.51 72
Economic Profit
Residual Income $46.36 $45.96 $47.21 76
ROIC Compounder $10.98 $15.17 $18.79 72
Growth Earnings
Growth-Adj P/E $25.90 $37.00 $48.10 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 68/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 25
How much profit the company makes from its sales and capital
Quality Growth 46
Are margins and returns getting better?
Cashflow 84
Do the profits arrive as real cash?
Financial strength 64
Debt, balance sheet and risk of trouble
Investment 99
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 100
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 96
Distance to the 52-week high, does not count
New shares 97
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors sold shares worth $1.3M and none bought.

  • SaleAnita GonzalesVP and CAO3× since Apr 20, 2026: 249 shares, avg. $119.64$29,790Oct 1, 202610b5-1 plan
  • SaleMaxwell KrakowiakPlease See Remarks1,631 shares at $144.53$235,728Sep 21, 202610b5-1 plan
  • SaleTajinder S VohraPlease See Remarks2× since Feb 2, 2026: 13,086 shares, avg. $124.88$1.6MSep 16, 202610b5-1 plan
  • SaleMiriame VictorPlease See Remarks1,862 shares at $97.13$180,856Feb 24, 202610b5-1 plan
  • SaleMichelle McMurry-HeathDirector600 shares at $97.26$58,356Feb 23, 2026
  • SaleJoel S GoldbergPlease See Remarks12,717 shares at $100.21$1.3MFeb 5, 202610b5-1 plan
  • SalePrahlad R. SinghPlease See Remarks, Director25,525 shares at $100.21$2.6MFeb 5, 202610b5-1 plan

Plus 13 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 4, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+3.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.5%
Start year 2020 (pandemic). Over 10 years: +3.1% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.3%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−17.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−17.5%
Dividend (yield on the price)0.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−20.0% vs 1.3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.27% → 13%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+21.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +18.7% a year for the price and +1.4% for the forecasts.
Forecast 2026 (sales)−0.1%
Forecast 2027 (sales)+5.4%
Projected 2028 (sales)+5.0%
Projected 2029 (sales)+4.6%
Projected 2030 (sales)+4.2%

RVTY screens overvalued: fair value 77% below the price. Compare with Thermo Fisher Scientific Inc →

Recent news

News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.
Note from the team Oct 11, 2026
AI conclusion: Business quality remains average overall, with stable cash metrics as the main strength while low ROE relative to margins represents the key weakness.
Main risk: AI adoption enabling smaller compound sets could reduce demand for Revvity's high-content screening tools and reagents that account for a large share of its preclinical life sciences revenue.
Bull case: Revvity could leverage its installed base and Signals platform to supply the wet-lab validation data and workflow tools that AI-driven drug design requires, expanding high-margin recurring revenue.
Bear case: If AI reduces the volume of compounds needing physical screening, Revvity's preclinical tools and reagents revenue could decline materially as pharma R&D shifts toward computational methods.
Revvity is acquiring Human Cell Design to strengthen its human-relevant cell models for metabolic disease drug discovery. This adds specialized beta cell lines and reagents that can pair with its screening and informatics platforms. Our models currently see the stock as overvalued. Will these new tools expand high-margin recurring revenue in life sciences faster than integration costs and competition erode margins?
Join the discussion →

Compare Revvity Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks

Beats the industry median on 4/14 measures
Overall it trails its industry peers.
Valuation
Quality Score 68 · Top 25%
Fair Value upside −76.8% · Bottom 25%
Profitability
Return on equity (12 months) 3.2% · Below median
Return on assets 2.0% · Below median
Net margin (12 months) 8.2% · Above median
Operating margin (12 months) 17.1% · Above median
Growth and dividend
Revenue growth (quarter YoY) 1.3% · Below median
Dividend yield (12 months) 0.2% · Bottom 25%
Balance sheet
Debt / equity 0.36× · Above median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (12 months) 76.3× · Priciest 25%
P/B 2.46× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 6.12× · Pricier than median
Price / free cash flow 35.1× · Pricier than median
EV/EBITDA 22.3× · Pricier than median
PEG 0.73× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)7 · sector 38
PAST (return on equity)13 · sector 15
HEALTH (low debt)82 · sector 95
DIVIDEND (yield)4 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Illumina, Inc ILMN $226.54 $262.03 +16% vs RVTY
IQVIA Holdings IQV $263.79 $288.85 +10% vs RVTY
WuXi AppTec Co 603259 ¥154.46 ¥164.66 +7% vs RVTY
Thermo Fisher Scientific Inc TMO $706.16 $686.04 −3% vs RVTY
Danaher Corporation DHR $234.93 $209.18 −11% vs RVTY
IDEXX Laboratories, Inc IDXX $698.55 $496.48 −29% vs RVTY
Mettler-Toledo International Inc MTD $1,723 $648.30 −62% vs RVTY
Agilent Technologies, Inc A $177.17 $64.53 −64% vs RVTY
Lonza Group LONN CHF 672.40 CHF 153.50 −77% vs RVTY
Waters Corporation WAT $467.60 $91.26 −80% vs RVTY

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Revvity Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Revvity Inc. Fair Value". https://www.fairvalue-calculator.com/stock/RVTY

Frequently asked questions

Is Revvity Inc. (RVTY) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $37.00 versus a price of $159.43, about 77% lower (overvalued).
What is the fair value of RVTY?
Our model-based fair value for Revvity Inc. is $37.00 (as of Nov 4, 2026), built from audited fundamentals. The current price: $159.43.
What is the quality score of RVTY?
Revvity Inc. has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Revvity Inc. (RVTY)?
Our model-based price target is the fair value of $37.00 (as of Nov 4, 2026) from 22 valuation models. Cautious scenario $27.61, optimistic scenario $47.21. It is a calculation from audited fundamentals, not an analyst target.
What is the Revvity Inc. stock forecast for 2026?
Our models put fair value at $37.00, about 77% lower versus a price of $159.43 (overvalued). Cautious scenario $27.61, optimistic scenario $47.21. The calculation is refreshed regularly with new filings.
What is the revenue of Revvity Inc. (RVTY)?
Revvity Inc. reported trailing-twelve-month revenue of about $2.9B (latest available figure, as of Nov 4, 2026).
Does Revvity Inc. pay a dividend?
Revvity Inc. currently shows a dividend yield of 0.18% relative to its recent price (as of Nov 4, 2026).
What growth is priced into Revvity Inc. (RVTY)?
For today's price to be fair in a discounted-cash-flow model, Revvity Inc. would have to grow free cash flow by +21.6 % per year for five years (discount rate 9.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -5.5 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of RVTY use?
Our models discount Revvity Inc. at 9.4 %: a base by market capitalisation (large), damped by beta 1.09, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Revvity Inc. that is +21.6 % per year a year over ten years, using the same discount rate (9.4 %) and the same formula as our fair value.
How much growth has Revvity Inc. (RVTY) delivered so far?
Over the past 5 years revenue at Revvity Inc. grew -5.5 % a year. The price currently implies +21.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Revvity Inc. (RVTY) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Revvity Inc. (+21.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Revvity Inc. (RVTY)?
The free-cash-flow yield on the price is 2.85 %: that much free cash flow Revvity Inc. produces per unit of market value. When it exceeds the discount rate of our models (9.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Revvity Inc. (RVTY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Revvity Inc. it is $37.00 per share (as of Nov 4, 2026), against a price of $159.43. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Revvity Inc. stock overvalued or undervalued in 2026?
As of Nov 4, 2026, RVTY trades above its calculated fair value: price $159.43, fair value $37.00, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RVTY?
No. The price is what the market pays today ($159.43); the fair value is what the company's own numbers justify ($37.00). For Revvity Inc. the two are $122.43 per share apart. That gap is exactly why we show both numbers side by side.
How much is Revvity Inc. worth?
The market values Revvity Inc. at about $17.8B (market capitalisation, as of Nov 4, 2026). Per share that is $159.43; our models calculate a fair value of $37.00 per share.
What do the bullish and bearish scenarios say about RVTY?
Our models span a range for Revvity Inc.: cautious scenario $27.61, base $37.00, optimistic $47.21 per share (as of Nov 4, 2026, price $159.43). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RVTY?
Revvity Inc. trades at a price-to-earnings ratio of 76.3 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $37.00 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 64.3 (reported for FY2025: 74.9). Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, 6 of the years ex one-offs: 37.0. Other multiples: PEG 0.7, P/B 2.5, P/S 6.1, EV/EBITDA 22.3.
What is the PEG ratio of RVTY?
The PEG ratio of Revvity Inc. is 0.73 (P/E divided by earnings growth, as of Nov 4, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Revvity Inc. (RVTY)?
Balance-sheet figures for Revvity Inc. (as of Nov 4, 2026): return on equity 3.2%, debt of 0.36 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is RVTY from its 52-week high?
Revvity Inc. trades at $159.43, about 4% below its 52-week high of $165.78 and 94% above the low of $82.21 (as of Nov 4, 2026). Distance from the high says nothing about value: that is what the fair value of $37.00 is for.
Which stocks are comparable to Revvity Inc.?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Revvity Inc. stock attractive at the current price?
The data as of Nov 4, 2026: price $159.43, calculated fair value $37.00 (−77%), Quality Score 68/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RVTY calculated?
We run Revvity Inc. through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $37.00, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6% above its aggregate fair value. Revvity Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Revvity Inc. (RVTY)?
The closing price on Nov 4, 2026 was $159.43. Our model-based fair value is $37.00, about 77% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Revvity Inc. right now?
The price sits above even our optimistic bull case ($47.21). The favourable scenario is already priced in. Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Revvity Inc. (RVTY) come from?
Earnings per share at Revvity Inc. grew +2.6 % a year from 2014 to 2025. Broken into its drivers: revenue per share +2.3 %, EBIT margin +1.0 %, tax rate −0.1 %, residual (interest, one-offs) −0.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Revvity Inc.

How large is the market capitalisation of Revvity Inc. (RVTY)?
The market capitalisation of Revvity Inc. is $17.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Revvity Inc. (RVTY)?
The price-to-sales ratio of Revvity Inc. is 6.12 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Revvity Inc. (RVTY)?
Earnings per share at Revvity Inc. are $2.09 (price ÷ EPS = P/E 76.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Revvity Inc. (RVTY)?
The dividend yield of Revvity Inc. is 0.2% (payout 11.5%, on adjusted earnings, reported 13.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Revvity Inc. (RVTY)?
The net margin of Revvity Inc. is 8.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Revvity Inc. (RVTY)?
The return on equity (ROE) of Revvity Inc. is 3.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Revvity Inc. (RVTY)?
On an EBIT basis the return on assets of Revvity Inc. is 4.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Revvity Inc. (RVTY)?
The operating margin of Revvity Inc. is 17.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Revvity Inc. (RVTY)?
Revenue at Revvity Inc. is growing +1.3% versus a year earlier (3y avg −4.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Revvity Inc. (RVTY)?
Earnings per share at Revvity Inc. are growing +1.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Revvity Inc. (RVTY) carry?
The net debt of Revvity Inc. is $2.6B (fiscal year 2025, ≈ 5.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Revvity Inc. in the live analysis

One click puts Revvity Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.